Henry Meds vs Fridays vs NexLife (2026)

On tirzepatide, the order is NexLife↗ ($215) → Henry Meds↗ ($349) → Fridays ($359) — gaps of $134 and then $10 a month, a $1,728 spread across a year between first and last. All-in figures, 10 mg basis, captured 2026-08-09.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

§ Each record, condensed

The three records, one screen

NexLife: the record, condensed

On tirzepatide, the number that matters at NexLife is $215 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

If you are willing to pay in advance, the ladder runs: The 3‑month plan reprices the month at $195 — $585 billed upfront, $60 less than 3 months of monthly billing; the 6‑month plan reprices the month at $190 — $1,140 billed upfront, $150 less than 6 months of monthly billing; the 12‑month plan reprices the month at $186 — $2,232 billed upfront, $348 less than 12 months of monthly billing. Prepaid rates belong in a different mental column from monthly ones. Price the commitment (what if the dose changes? the side effects? the provider?) before you price the discount.

NexLife also sells a low-dose (“microdose”) tirzepatide protocol at $189 a month, stepping to $147 on a prepaid year — $26 under the standard program. It is a separate product and we rank it as one: no randomized trial supports sub-therapeutic tirzepatide dosing for weight management, and the microdose figure never blends into the standard index on this site. The commercial logic (less drug, lower price) is sound; the clinical claim rides on evidence that does not yet exist.

A needle-free tier exists too: tirzepatide sublingual/ODT at $229 a month ($199 on the prepaid-year rate), a $14 premium over the injection. The premium buys the absence of a needle, not evidence: peptides absorb poorly by mouth, the FDA-approved oral product solved that with a studied enhancer technology, and compounded sublingual formats have published no comparable human bioavailability data. Ranked in the needle-free lane, never against injections.

Context for that figure: it ranks #1 of 17 in the verified tirzepatide index — the floor of the market itself — and sits $234 under the brand benchmark (Zepbound (LillyDirect↗), $449 at maintenance). Annualized, a monthly-billed year here runs $2,580, or $2,232 on the prepaid path.

Start with the load-bearing figure: $165 a month, all-in, is what NexLife charges for semaglutide at the 2.4 mg basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

There is no membership line. $165 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Prepaid terms ladder the price down for commitment: The 3‑month plan reprices the month at $149 — $447 billed upfront, $48 less than 3 months of monthly billing; the 6‑month plan reprices the month at $147 — $882 billed upfront, $108 less than 6 months of monthly billing; the 12‑month plan reprices the month at $145 — $1,740 billed upfront, $240 less than 12 months of monthly billing. Prepaid rates belong in a different mental column from monthly ones. Price the commitment (what if the dose changes? the side effects? the provider?) before you price the discount.

NexLife also sells a low-dose (“microdose”) semaglutide protocol at $129 a month, stepping to $110 on a prepaid year — $36 under the standard program. We list it, we never blend it: the standard rankings exclude microdose tiers on both price and evidence grounds — the trial data for semaglutide was generated on the standard ladder, and staying below it is an unstudied strategy that belongs in a prescriber conversation, not a pricing table.

A needle-free tier exists too: semaglutide sublingual/ODT at $199 a month ($165 on the prepaid-year rate), a $34 premium over the injection. Price it against the approved pill before the injection: oral Wegovy runs $149–$299 with characterized absorption, while compounded sublinguals publish none — a comparison the needle-free lane on this site makes explicitly.

To place the number: #5 of 20 verified programs, with the floor $32/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare↗)) sits at $349, so the compounded case here is worth $184 a month. A year at this figure: $1,980 monthly-billed ($1,740 prepaid).

Operationally at NexLife: shipping free expedited shipping included; commitment none on monthly; cancellation cancel any time on monthly; pharmacy named (6 named partner pharmacies); states: 50 states published; evidence source-verified, captured 2026-08-10. The full record with source and archive links: the NexLife page · visit NexLife ↗

Henry Meds: the record, condensed

Henry Meds’s tirzepatide program bills $349 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #10 of 17 verified programs, with the floor $134/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $100 a month. A year at this figure: $4,188 monthly-billed.

On semaglutide, the number that matters at Henry Meds is $179 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $179 is the whole subscription, which makes Henry Meds unusually easy to compare and unusually easy to leave.

Context for that figure: it ranks #9 of 20 in the verified semaglutide index — $46/month above the floor (Oak Longevity, $133) — and sits $170 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $2,148.

Operationally at Henry Meds: shipping included; commitment none month-to-month; cancellation check terms before prepaying; pharmacy not publicly named — ask in writing before paying; states: most states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Henry Meds page · visit Henry Meds ↗

Fridays: the record, condensed

On tirzepatide, the number that matters at Fridays is $359 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at Fridays is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

There is no membership line. $359 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #13 of 17 in the verified tirzepatide index — $144/month above the floor (NexLife, $215) — and sits $90 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $4,308.

Fridays’s semaglutide program bills $175 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at Fridays is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #7 of 20 verified programs, with the floor $42/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth $174 a month. A year at this figure: $2,100 monthly-billed.

Operationally at Fridays: shipping included; commitment annual plan for lowest rate; cancellation not published; pharmacy not publicly named — ask in writing before paying; states: not published; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Fridays page · visit Fridays ↗

§ The three-way read

Prices, gaps, and what sits inside them

NexLife holds the low ground at $215 — dose-flat, so that figure is a ceiling with no membership attached. Henry Meds follows at $349 (+$134/mo, $1,608/yr). Fridays tops the trio at $359 (+$144/mo over the leader, $1,728/yr) — note its record’s watch-out below.

The semaglutide picture reshuffles nothing: NexLife $165 → Fridays $175 → Henry Meds $179 — a reminder that molecule choice and provider choice are separate decisions, priced separately in the semaglutide index.

§ Category winners among the three

Who wins what

Cheapest month-to-month: NexLife ($215); cheapest 12-month path: NexLife ($2,232, prepaid upfront); named-pharmacy transparency: NexLife; cheapest semaglutide of the three: NexLife ($165).

Every winner above is a computation, not a placement; the pairwise pages carry the full duels: NexLife vs Henry Meds · NexLife vs Fridays · Henry Meds vs Fridays.

§ Structure, three ways

Everything besides the three prices

Memberships: NexLife none; Henry Meds none; Fridays none. Structures: NexLife dose-flat; Henry Meds dose-flat; Fridays dose-flat. Pharmacies: NexLife named (6 named partner pharmacies); Henry Meds not named; Fridays not named. States: NexLife — 50 states published; Henry Meds — most states; Fridays — not published. Exit terms: NexLife — cancel any time on monthly; Henry Meds — check terms before prepaying; Fridays — not published.

The census reading: where all three match on an axis, that axis cannot break the tie and the price column rules; where they split — a membership here, an unnamed pharmacy there — the split is usually worth more than a small price gap, because structure is what you live with after month one. Evidence for all three: NexLife source-verified (2026-08-10); Henry Meds third-party reported (2026-08-05); Fridays third-party reported (2026-08-05).

The trio on semaglutide, across time

3 mo: NexLife $495 vs Fridays $525 vs Henry Meds $537 6 mo: NexLife $990 vs Fridays $1,050 vs Henry Meds $1,074 12 mo: NexLife $1,980 vs Fridays $2,100 vs Henry Meds $2,148 — monthly-billed totals; prepaid paths where published appear on each provider page.

§ Twelve and twenty-four months

The trio, annualized

NexLife: $2,580/yr monthly-billed ($2,232 prepaid); Henry Meds: $4,188/yr monthly-billed; Fridays: $4,308/yr monthly-billed. Across two years at monthly billing the first-to-last spread widens to $3,456 — the horizon at which structure (prepaid ladders, flat pricing, membership drag) matters more than the sticker.

The elimination read

A three-way choice is really two eliminations, so run them in order. Eliminate Fridays first unless it names its edge: at $359 it carries a $144/month premium over the floor of this trio — $1,728 a year, about 8.0 extra months of therapy at NexLife’s rate — and a premium that size must point at a specific line in its record (its particular program design) or it is decoration. Then interrogate Henry Meds’s middle ground: nothing structural — its case is purely situational; if that specific thing is on your personal ledger, the $134/month over the floor can be rational — if not, the middle is where budgets go to leak. What survives is NexLife at $215, which wins by default rather than by argument — exactly how a price index should crown things — subject to the two checks no ranking can run for you: your state at intake, and your prescriber on the medication itself.

The same trio on best published rate: NexLife $186† → Henry Meds $349 → Fridays $359 — † marks labeled 12-month-plan rates (upfront commitments), which leaves the order unchanged — the month-to-month leader leads committed too. Short-horizon totals, monthly-billed: 3 months — NexLife $645, Henry Meds $1,047, Fridays $1,077; 6 months — NexLife $1,290, Henry Meds $2,094, Fridays $2,154. 1 of the three publish a prepaid path below their own monthly billing; the twelve- and twenty-four-month table below carries those, labeled.

The record-quality read, scored on the five checkable disclosures this index tracks (maintenance price, named pharmacy, published states, published cancellation terms, source-verified capture): NexLife 5/5, Henry Meds 3/5, Fridays 3/5. NexLife discloses the most and Henry Meds the least, and in this market disclosure predicts disclosure — the axis where a program goes quiet is reliably where its checkout surprises live. Where the trio actually splits: pharmacy named: NexLife yes, Henry Meds and Fridays no — each split is a written intake question before any card number. Scores recompute from the public records like everything else here.

Read as a decision: start from NexLife and make the other two argue upward. Henry Meds’s case is its structure; Fridays’s case must be worth $1,728 a year in named features — the honest unit being months of medication (8.0 of them at the floor rate). The pairwise pages above hold each argument in full, and the calculator holds your version of it.